Soluble B7-H3 as a Biomarker for Osteosarcoma

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jul 5, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a substance called soluble B7-H3 (sB7-H3) to see if it can be used as a marker to help manage osteosarcoma, a type of bone cancer. Researchers want to find out if the levels of sB7-H3 in the blood can provide important information about the disease and its treatment. The study is currently looking for participants, including individuals aged 4 to 82 who have been diagnosed with high-grade osteosarcoma and have not yet received any treatment.

To be eligible, participants need to be in good health with a performance status of ECOG 0 or 1, meaning they are fully active or only slightly restricted in their daily activities. Those who have complete medical records and can tolerate blood tests and neoadjuvant chemotherapy (a treatment given before surgery) may be considered for the study. If you or someone you know meets these criteria, participating in this trial could contribute to understanding how sB7-H3 levels relate to osteosarcoma and potentially improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • High Grade osteosarcoma verified with pathologic diagnosis.
• • systemic treatment-naive before the first time Blood drawing.
• • ECOG 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol neoadjuvant chemotherapy.
• • All radiographs are complete for clinical evaluation.
• Exclusion Criteria:
• • Patients who Can't tolerate blood drawing.
• • Patients without complete medical records in PKUPH system.
• • Patients who can't tolerate PKUPH-OS-02 neoadjuvant chemotherapy.
• • other conditions that investigators think are not suitable for this study.